Differential modulation of agonist potency and receptor coupling by mutations of Ser388Tyr and Thr389Pro at the junction of transmembrane domain VI and the third extracellular loop of human M1 muscarinic acetylcholine receptors

Molecular Pharmacology

Volumn 56, Issue 4, 1999, Pages 775-783

  Huang, Xi Ping ^a   Williams, Frederick E ^b   Peseckis, Steven M ^b   Messer Jr , William S ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ARECOLINE; CARBACHOL; CHOLINE; MUSCARINIC M1 RECEPTOR; OXOTREMORINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG POTENCY; DRUG RECEPTOR BINDING; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY;

AMINO ACID SEQUENCE; BINDING, COMPETITIVE; CELL LINE; HUMANS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; MUSCARINIC AGONISTS; MUTATION; PROLINE; PROTEIN CONFORMATION; RADIOLIGAND ASSAY; RECEPTORS, MUSCARINIC; SERINE; THREONINE; TYROSINE;

EID: 0032853198     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bhogal N, Donnelly D and Findlay JB (1994). The ligand binding site of the neurokinin 2 receptor: Site-directed mutagenesis and identification of neurokinin A binding residues in the human neurokinin 2 receptor. J Biol Chem 269:27269-27274.
2. Blüml K, Mutschler E and Wess J (1994) Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J Biol Chem 269:18870-18876.
3. Bonner TI, Young AC, Brann MR and Buckley NJ (1988) Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1:403-410.
4. Caulfield MP (1993) Muscarinic receptors-characterization, coupling and function. Pharmacol Ther 58:319-379.
5. Caulfield MP and Birdsall NJ (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279-290.
6. Chen C and Okayama H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7:2745-2752.
7. Edvardsen O and Kristiansen K (1997) Computerization of mutant data: The tinyGRAP mutant database. 7TM J 6:1-6.
8. Ellis J, Porter DJ and Seidenberg M (1998) Homologous mutations increase agonist affinity at m1, m3 and m5 muscarinic receptors. Soc Neurosci 24:624.
9. Fraser CM, Wang CD, Robinson DA, Gocayne JD and Venter JC (1989) Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: Conserved aspartic acids play important roles in receptor function. Mol Pharmacol 36:840-847.
10. Gether U, Johansen TE, Snider RM, Lowe JA, Nakanishi S and Schwartz TW (1993) Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist. Nature (Lond) 362:345-348.
11. Gether U, Nilsson L, Lowe JA and Schwartz TW (1994) Specific residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345 [corrected; published erratum appears in J Biol Chem (1994) 269:32708]. J Biol Chem 269:23959-23964.
12. Gether U, Nilsson L, Lowe JA and Schwartz TW (1994) Specific residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345 [corrected; published erratum appears in J Biol Chem (1994) 269:32708]. J Biol Chem 269:23959-23964.
13. Hjorth SA, Schambye HT, Greenlee WJ and Schwartz TW (1994) Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J Biol Chem 269:30953-30959.
14. Hjorth SA, Thirstrup K, Grandy DK and Schwartz TW (1995) Analysis of selective binding epitopes for the κ-opioid receptor antagonist nor-binaltorphimine. Mol Pharmacol 47:1089-1094.
15. Huang XP, Nagy PI, Williams FE, Peseckis SM and Messer WS Jr (1999) Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with m1 muscarinic acetylcholine receptors. Br J Pharmacol 126:735-745.
16. Huang XP, Williams FE, Peseckis SM and Messer WS Jr (1998) Pharmacological characterization of human m1 muscarinic acetylcholine receptors with double mutations at the junction of TM VI and the third extracellular domain. J Pharmacol Exp Ther 286:1129-1139.
17. Huang XY, Morielli AD and Peralta EG (1994) Molecular basis of cardiac potassium channel stimulation by protein kinase A. Proc Natl Acad Sci USA 91:624-628.
18. Hulme EC, Birdsall NJ and Buckley NJ (1990) Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol 30:633-673.
19. Jones RM, Hjorth SA, Schwartz TW and Portoghese PS (1998) Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. J Med Chem 41:4911-4914.
20. 2 adrenergic receptor. Life Sci 62:1509-1512.
21. Kremer H, Kraaij R, Toledo SP, Post M, Fridman JB, Hayashida CY, van Reen M, Milgrom E, Ropers HH and Mariman E (1995) Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nat Genet 9:160-164.
22. Kristiansen K, Dahl SG and Edvardsen O (1996) A database of mutants and effects of site-directed mutagenesis experiments on G protein-coupled receptors. Proteins 26:81-94.
23. Kyle DJ, Chakravarty S, Sinsko JA and Stormann TM (1994) A proposed model of bradykinin bound to the rat B2 receptor and its utility for drug design. J Med Chem 37:1347-1354.
24. Matsui H, Lazareno S and Birdsall NJ (1995) Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol Pharmacol 47:88-98.
25. Nardone J and Hogan PG (1994) Delineation of a region in the B2 bradykinin receptor that is essential for high-affinity agonist binding. Proc Natl Acad Sci USA 91:4417-4421.
26. Nordvall G and Hacksell U (1993) Binding-site modeling of the muscarinic m1 receptor: A combination of homology-based and indirect approaches. J Med Chem 36:967-976.
27. Novotny EA, Bednar DL, Connolly MA, Connor JR and Stormann TM (1994) Mutation of aspartate residues in the third extracellular loop of the rat B2 bradykinin receptor decreases affinity for bradykinin. Biochem Biophys Res Commun 201: 523-530.
28. Samama P, Cotecchia S, Costa T and Lefkowitz RJ (1993) A mutation-induced activated state of the beta 2-adrenergic receptor: Extending the ternary complex model. J Biol Chem 268:4625-4636.
29. Sautel M, Martinez R, Munoz M, Peitsch MC, Beck-Sickinger AG and Walker P (1995) Role of a hydrophobic pocket of the human Y1 neuropeptide Y receptor in ligatid binding. Mol Cell Endocrinol 112:215-222.
30. Spalding TA, Burstein ES, Brauner-Osborne H, Hill-Eubanks D and Brann MR (1995) Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis. J Pharmacol Exp Ther 275:1274-1279.
31. Spalding TA, Burstein ES, Henderson SC, Ducote KR and Brann MR (1998) Identification of a ligand-dependent switch within a muscarinic receptor. J Biol Chem 273:21563-21568.
32. Spalding TA, Burstein ES, Wells JW and Brann MR (1997) Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6. Biochemistry 36:10109-10116.
33. Valiquette M, Vu HK, Yue SY, Wahlestedt C and Walker P (1996) Involvement of Trp-284, Val-296, and Val-297 of the human delta-opioid receptor in binding of delta-selective ligands. J Biol Chem 271:18789-18796.
34. Walker P, Munoz M, Martinez R and Peitsch MC (1994) Acidic residues in extracellular loops of the human Y1 neuropeptide Y receptors are essential for ligand binding. J Biol Chem 269:2863-2869.
35. Ward JS, Merritt L, Klimkowski VJ, Lamb ML, Mitch CH, Bymaster FP, Sawyer B, Shannon HE, Olesen PH and Honore T (1992) Novel functional M1 selective muscarinic agonists: 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines: Construction of a molecular model for the M1 pharmacophore. J Med Chem 35:4011-4019.
36. Ward SDJ and Hulme EC (1997) Alanine scanning mutagenesis in transmembrane domain six of the rat m1-muscarinic acetylcholine receptor (rat m1-receptor). Br J Pharmacol 120:284P.
37. Wess J (1993) Mutational analysis of muscarinic acetylcholine receptors: Structural basis of ligand/receptor/G protein interactions. Life Sci 53:1447-1463.
38. Wess J (1996) Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 10:69-99.
39. Wess J, Gdula D and Brann MR (1991) Site-directed mutagenesis of the m3 muscarinic receptor: Identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. EMBO J 10:3729-3734.
40. Wess J, Maggio R, Palmer JR and Vogel Z (1992) Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation: A study with m3 muscarinic receptor point mutants. J Biol Chem 267:19313-19319.
41. 2-adrenergic receptor can modulate receptor/G protein affinity. Mol Pharmacol 53:524-529.